Pacira Pharma (PCRX) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Wedbush Raises Price Target on Pacira Pharma (PCRX) Following 3Q Beat
October 27, 2015 5:20 PM EDTWedbush reiterated an Outperform rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target to $113.00 (from $106.00), following the company's 3Q earnings results. Total revenues of $62.2MM beat consensus of $60.4MM and diluted GAAP EPS of $0.08 also beat consensus of $0.02.
Analyst Liana Moussatos... More
